The Proposal for a Directive on Defective Products: A Game Changer for Innovative Medicinal Products - Université de Bourgogne Accéder directement au contenu
Article Dans Une Revue European Journal of Health Law Année : 2024

The Proposal for a Directive on Defective Products: A Game Changer for Innovative Medicinal Products

Résumé

Abstract At the end of 2022, the European Commission published a proposal for a directive to revise the strict liability regime introduced in 1985. Although the main goal of this new proposal is to adapt the regulations to information technologies such as artificial intelligence, it has multiple impacts on other economic sectors, including the pharmaceutical market. Therefore, this proposal could change the deal in terms of liability in this specific market. Indeed, the proposal modifies the burden of proof, which can be quite challenging to establish in the case of adverse effects of medicinal products. It introduces a possible presumption of liability for a manufacturer who fails to communicate, to a court, the information they required, which might jeopardise the protection of trade secrets and commercial confidentiality. In addition, the proposal also extends the limitation period, and more importantly, it mandates the application of the ‘development risk defence.’

Domaines

Droit
Fichier non déposé

Dates et versions

hal-04594288 , version 1 (30-05-2024)

Identifiants

Citer

Mathieu Guerriaud, Valérie Siranyan. The Proposal for a Directive on Defective Products: A Game Changer for Innovative Medicinal Products. European Journal of Health Law, 2024, 31 (1), pp.1-15. ⟨10.1163/15718093-bja10117⟩. ⟨hal-04594288⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More